RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the signing of a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit foundation focused on the development of new drugs and new formulations of existing drugs for patients suffering from some of the world’s most neglected communicable diseases.
